ReviewJournal of clinical medicine2025
Long-Term Cardiovascular Risk and Maternal History of Pre-Eclampsia.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Biomarkers of endothelial glycocalyx dysfunction in pregnancy: a systematic review of clinical relevance and detection techniques.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Pooled it
- Arterial stiffness after 6 weeks postdelivery in women with a history of hypertensive disorders of pregnancy: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Understanding physiological adaptations of pregnancy to the chronic hypoxia of high altitude to inform obstetrical and neonatal care.Physiological reviews · 2026Review
- The endothelin-1/TLR4/NF-κB/NLRP3 inflammasome axis in preeclampsia: a review of a pathological feed-forward loop and therapeutic frontier.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Recurrent hypertensive disorders of pregnancy and subsequent maternal coronary heart disease, stroke, and all-cause mortality.Pregnancy (Hoboken, N.J.) · 2026Article
- The Immuno-Cardiovascular Storm of Pre-Eclampsia: Cytokine-Mediated Endothelial Injury, Thrombosis, and Maternal Cardiovascular Instability.Comprehensive Physiology · 2026Review
- Maternal Cardiovascular Phenotype in Fetal Growth Restriction with or Without Pre-Eclampsia: Insights from Echocardiography and Clinical Implications.Diagnostics (Basel, Switzerland) · 2026Review
- Overlap of Gestational Diabetes Mellitus and Pre-eclampsia: A Scoping Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Severity-Dependent Modulation of Red Blood Cell Aging Patterns in Preeclampsia: Insights from Calorimetry and Atomic Force Microscopy.International journal of molecular sciences · 2026Article
- Hypertensive Disorders of Pregnancy and Early-Life Cardiovascular Disease: Bridging the Knowledge Gap among Healthcare Providers.Current atherosclerosis reports · 2026Review
- Identifying systemic vulnerability phenotypes associated with programmed regimens in frozen embryo transfer: a secondary analysis of a multicentre randomized clinical trial.Frontiers in medicine · 2026Article
- Fetal fractions mediate the association between total cell-free DNA and preeclampsia risk in a non-invasive prenatal testing cohort.Human genomics · 2025Article
- The Etiopathogenesis of Preeclampsia: Where Do We Stand Now?Journal of clinical medicine · 2025Review
- Spatiotemporal patterns and future trends of global ischemic stroke burden.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pre-eclampsia is a severe pregnancy complication affecting 5-8% of pregnancies worldwide, marked by high blood pressure and organ damage typically occurring after 20 weeks of gestation. It is a leading cause of maternal and fetal morbidity and mortality. Though its exact cause is unknown, it involves placental abnormalities and improper blood vessel development. Risk factors include a history of pre-eclampsia, chronic hypertension, diabetes, obesity, and autoimmune disorders. Symptoms include high blood pressure, proteinuria, headaches, vision changes, and abdominal pain. Untreated, it can lead to seizures, stroke, preterm birth, or death. Delivery is the definitive treatment, with management strategies such as monitoring and blood pressure control. Pre-eclampsia significantly increases long-term cardiovascular disease (CVD) risks, including hypertension, ischemic heart disease, and stroke, linked to shared mechanisms like endothelial dysfunction and inflammation. Women with severe or recurrent pre-eclampsia have heightened risks, often developing chronic hypertension within a decade postpartum. It also impacts offspring, with daughters at elevated risk for pre-eclampsia and CVD. Hypertensive disorders of pregnancy, including pre-eclampsia, induce changes like left ventricular hypertrophy and diastolic dysfunction, raising risks for heart failure with preserved ejection fraction and coronary atherosclerosis. Overlapping with peripartum cardiomyopathy, pre-eclampsia underscores a spectrum of pregnancy-related cardiovascular disorders. Long-term monitoring and lifestyle interventions are crucial for managing risks, with research into genetic and biological mechanisms offering the potential for targeted prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.